- Home
- AFRM vs ROIV Comparison
AFRM vs ROIV Comparison
Compare AFRM & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AFRM | ROIV |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.3B | 26.2B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AFRM | ROIV |
|---|---|---|
| Price | $79.05 | $36.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 25 | 9 |
| Target Price | ★ $84.52 | $28.94 |
| AVG Volume (30 Days) | 3.2M | ★ 5.1M |
| Earning Date | 05-07-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 108.98 | N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $3,224,412,000.00 | $8,260,000.00 |
| Revenue This Year | $30.78 | N/A |
| Revenue Next Year | $23.95 | $744.61 |
| P/E Ratio | $87.00 | ★ N/A |
| Revenue Growth | ★ 38.80 | N/A |
| 52 Week Low | $42.10 | $11.54 |
| 52 Week High | $100.00 | $37.00 |
Technical Indicators
Market Signals| Indicator | AFRM | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 55.88 | 60.08 |
| Support Level | $71.24 | $33.01 |
| Resistance Level | $79.79 | $36.35 |
| Average True Range (ATR) | 3.44 | 1.23 |
| MACD | 0.36 | 0.12 |
| Stochastic Oscillator | 82.44 | 88.86 |
Price Performance
Historical ComparisonAbout AFRM Affirm Holdings Inc.
Founded in 2012, Affirm is a market leader in the buy now, pay later space with around $36 billion in transaction volume in fiscal 2025. Affirm offers both zero-interest financing, which is merchant subsidized, and interest-bearing loans, which function as personal loans that are approved on a per-transaction basis. Over 70% of Affirm's transaction volume comes from its interest-bearing loans, which also constitute the majority of its revenue. Affirm primarily operates in the United States, which accounted for more than 95% of its revenue in 2025, but it has also expanded to Canada and the United Kingdom.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.